110 related articles for article (PubMed ID: 25636858)
1. The influence of breathing mode on tobramycin serum levels using the I-neb AAD system in adults with cystic fibrosis.
van Velzen AJ; Uges JW; Le Brun PP; Shahbabai P; Touw DJ; Heijerman HG
J Cyst Fibros; 2015 Nov; 14(6):748-54. PubMed ID: 25636858
[TBL] [Abstract][Full Text] [Related]
2. Lung Deposition of Alpha1-Proteinase Inhibitor (Human) (A1-PI[H]) Inhalation Solution Using Two Inhalation Modes of the I-neb Adaptive Aerosol Delivery (AAD) System in Healthy Subjects and Subjects with Cystic Fibrosis.
Häussermann S; Winnips C; Edelman J; Kappeler D; Herpich C; Ehlich H; Zanker D; Kietzig C; Sommerer K
J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):242-50. PubMed ID: 26669827
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization.
van Velzen AJ; Bos AC; Touw DJ; Tiddens HA; Heijerman HG; Janssens HM
J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):273-80. PubMed ID: 26716357
[TBL] [Abstract][Full Text] [Related]
4. Mode of breathing-tidal or slow and deep-through the I-neb Adaptive Aerosol Delivery (AAD) system affects lung deposition of (99m)Tc-DTPA.
Nikander K; Prince I; Coughlin S; Warren S; Taylor G
J Aerosol Med Pulm Drug Deliv; 2010 Apr; 23 Suppl 1(Suppl 1):S37-43. PubMed ID: 20373908
[TBL] [Abstract][Full Text] [Related]
5. Aerosolization of tobramycin (TOBI) with the PARI LC PLUS reusable nebulizer: which compressor to use? Comparison of the CR60 to the PortaNeb compressor.
Westerman EM; Boer AH; Touw DJ; Brun PP; Roldaan AC; Frijlink HW; Heijerman HG
J Aerosol Med Pulm Drug Deliv; 2008 Sep; 21(3):269-80. PubMed ID: 18759658
[TBL] [Abstract][Full Text] [Related]
6. Domiciliary experience of the Target Inhalation Mode (TIM) breathing maneuver in patients with cystic fibrosis.
Denyer J; Black A; Nikander K; Dyche T; Prince I
J Aerosol Med Pulm Drug Deliv; 2010 Apr; 23 Suppl 1(Suppl 1):S45-54. PubMed ID: 20373909
[TBL] [Abstract][Full Text] [Related]
7. A pharmacokinetics and safety comparison of a highly concentrated tobramycin solution with TOBI.
Griese M; Eismann C; Börner G; Denk O; Schierholz JM; Keller M; Mazurek H; Kappler M
J Aerosol Med Pulm Drug Deliv; 2014 Jun; 27(3):185-92. PubMed ID: 23789705
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and safety of tobramycin nebulization with the I-neb and PARI-LC Plus in children with cystic fibrosis: A randomized, crossover study.
van Velzen AJ; Uges JWF; Heijerman HGM; Arets BGM; Nuijsink M; van der Wiel-Kooij EC; van Maarseveen EM; van Zanten GA; Pullens B; Touw DJ; Janssens HM
Br J Clin Pharmacol; 2019 Sep; 85(9):1984-1993. PubMed ID: 31112621
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis.
Hubert D; Leroy S; Nove-Josserand R; Murris-Espin M; Mely L; Dominique S; Delaisi B; Kho P; Kovarik JM
J Cyst Fibros; 2009 Sep; 8(5):332-7. PubMed ID: 19651542
[TBL] [Abstract][Full Text] [Related]
10. The I-neb Adaptive Aerosol Delivery System enhances delivery of alpha1-antitrypsin with controlled inhalation.
Geller DE; Kesser KC
J Aerosol Med Pulm Drug Deliv; 2010 Apr; 23 Suppl 1(Suppl 1):S55-9. PubMed ID: 20373910
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis.
Geller DE; Pitlick WH; Nardella PA; Tracewell WG; Ramsey BW
Chest; 2002 Jul; 122(1):219-26. PubMed ID: 12114362
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two tobramycin nebuliser solutions: pharmacokinetic, efficacy and safety profiles of T100 and TNS.
Sands D; Sapiejka E; Gąszczyk G; Mazurek H;
J Cyst Fibros; 2014 Dec; 13(6):653-60. PubMed ID: 24836961
[TBL] [Abstract][Full Text] [Related]
13. Inhalation of tobramycin in patients with cystic fibrosis: comparison of two methods.
Dopfer R; Brand P; Müllinger B; Hunger T; Häussermann S; Meyer T; Scheuch G; Siekmeier R
J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 1):141-54. PubMed ID: 18204125
[TBL] [Abstract][Full Text] [Related]
14. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
Al-Aloul M; Nazareth D; Walshaw M
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis.
Touw DJ; Jacobs FA; Brimicombe RW; Heijerman HG; Bakker W; Briemer DD
Antimicrob Agents Chemother; 1997 Jan; 41(1):184-7. PubMed ID: 8980777
[TBL] [Abstract][Full Text] [Related]
16. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system.
Geller DE; Rosenfeld M; Waltz DA; Wilmott RW;
Chest; 2003 Jan; 123(1):28-36. PubMed ID: 12527599
[TBL] [Abstract][Full Text] [Related]
17. Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring.
Stenbit AE; Bullington WM; Heh JL; Flume PA
J Cyst Fibros; 2013 Jul; 12(4):403-6. PubMed ID: 23266092
[TBL] [Abstract][Full Text] [Related]
18. Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis.
Coates AL; Denk O; Leung K; Ribeiro N; Chan J; Green M; Martin S; Charron M; Edwardes M; Keller M
Pediatr Pulmonol; 2011 Apr; 46(4):401-8. PubMed ID: 21438171
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Target Inhalation Mode (TIM) breathing maneuver in simulated nebulizer therapy in patients with cystic fibrosis.
Denyer J; Prince I; Dixon E; Agent P; Pryor J; Hodson M
J Aerosol Med Pulm Drug Deliv; 2010 Apr; 23 Suppl 1(Suppl 1):S29-36. PubMed ID: 20373907
[TBL] [Abstract][Full Text] [Related]
20. Effect of nebulizer configuration on delivery of aerosolized tobramycin.
O'Riordan TG; Amram JC
J Aerosol Med; 1997; 10(1):13-23. PubMed ID: 10166359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
